Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Appoints Daniel Char as Senior Vice President and Chief Legal Officer
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 21, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Daniel Char , JD, has been appointed Senior Vice President and Chief Legal Officer.
View HTML
Toggle Summary ImmunoGen Announces FDA Accelerated Approval of ELAHERE™ (mirvetuximab soravtansine-gynx) for the Treatment of Platinum-Resistant Ovarian Cancer
ELAHERE is the First ADC Approved by FDA for Platinum-Resistant Ovarian Cancer Indication Covers Patients with One to Three Prior Systemic Treatment Regimens, Regardless of Prior Avastin ® Use VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the Companion Diagnostic to Identify Ovarian Cancer Patients
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and Third Quarter 2022 Financial Results
Launch Preparations Completed Ahead of November 28, 2022 PDUFA Date Presentations at ESMO, IGCS, and ESGO Highlight Mirvetuximab’s Potential to Become New Standard of Care and Combination Agent of Choice in   FRα-Positive Ovarian Cancer Initial Data from Pivotal Phase 2 CADENZA Study Demonstrated
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 1, 2022-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on October 31, 2022 , the compensation committee of the Company’s Board of Directors approved
View HTML
Toggle Summary ImmunoGen Announces Departure of Chief Commercial Officer
WALTHAM, Mass. --(BUSINESS WIRE)--Nov. 1, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Kristen Harrington-Smith , Senior Vice President and Chief Commercial Officer (CCO), will be
View HTML
Toggle Summary ImmunoGen Presents Retrospective Analysis of Extended Treatment Benefit from Multiple Trials of Mirvetuximab Soravtansine in Ovarian Cancer at ESGO
Patients with Extended Treatment Benefit Showed an Objective Response Rate of 77.5% and a Median Duration of Response of 22.1 Months Overall Adverse Event Profile Observed Consistent with Known Safety Profile of Mirvetuximab with Minimal Cumulative Toxicities Study Outcomes in Patients with
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2022 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 20, 2022-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 4, 2022 to discuss its
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 3, 2022-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on September 30, 2022 , the compensation committee of the Company’s Board of Directors approved
View HTML
Toggle Summary ImmunoGen Presents Comprehensive Updates for Mirvetuximab Soravtansine Combination Data in Ovarian Cancer at IGCS
Mirvetuximab Plus Bevacizumab Demonstrated Meaningful Efficacy in Recurrent FRα-Positive Ovarian Cancer Across a Broad Range of FRα Expression Regardless of Prior Treatment; Data to be Highlighted in Oral Presentation Additional Clinical Benefit Outcomes from Pivotal SORAYA Study Also Reported
View HTML
Toggle Summary ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming Guggenheim Nantucket Therapeutics Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 14, 2022-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller , Chief Financial Officer, will participate in a fireside chat at the upcoming
View HTML